Clear Up Confusion With Biosimilars

November 2022

Biosimilars will be in the spotlight again...with up to 12 biosimilars for adalimumab (Humira) slated for 2023.

Biosimilars aren’t generics. It’s not possible to create an exact copy of the original “reference” biologic...since biologics contain larger, more complex molecules than most traditional drugs.

Biosimilars must show no clinically meaningful differences from the reference biologic in safety, purity, and potency.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote